
Methylphenidate for ADHD in Children and Adolescents
Abstract
The therapeutic effectiveness of methylphenidate (MPH) (0.3 mg/kg) in attention-deficit hyperactivity disorder (ADHD) was compared during childhood (ages 8 to 11 years) and adolescence (ages 12 to 14.5 years) in a retrospective follow-up study of 16 patients who had completed double-blind, placebo-controlled, crossover trials during two separate summer treatment programs at the Western Psychiatric Institute, University of Pittsburgh Medical Center, PA.
DOI: https://doi.org/10.15844/pedneurbriefs-12-3-10 | Journal eISSN: 2166-6482
Language: English
Page range: 23 - 24
Published on: Mar 1, 1998
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
© 1998 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.